tbuckley/cabot-search huggingface dataset:
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence—Reply
Authors: T. Jonathan Yang, Daniel R. Gomez, C. Jillian Tsai
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study
Authors: Federica Maritati, Francesco Peyronel, Paride Fenaroli, Francesco Pegoraro, Vieri Lastrucci, Giuseppe D. Benigno, Alessandra Palmisano, Giovanni M. Rossi, Maria L. Urban, Federico Alberici, Paolo Fraticelli, Giacomo Emmi, Massimo Corradi, Augusto Vaglio
Journal: Arthritis & Rheumatology (2021)

Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Environmental agents and occupational exposures may confer susceptibility to EGPA, but data are scarce. This study was undertaken to investigate the association between occupational exposures (e.g., silica, farming, asbestos, and organic solvents) and other environmental agents (e.g., smoking) and the risk of EGPA. Methods Patients with newly diagnosed EGPA (n = 111) and general population controls (n = 333) who were matched for age, sex, and geographic area of origin were recruited at a national referral center for EGPA. Exposures were assessed using a dedicated questionnaire administered by a specialist in occupational medicine, under blinded conditions. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Results Exposures to silica (OR 2.79 [95% CI 1.55–5.01], P = 0.001), organic solvents (OR 3.19 [95% CI 1.91–5.34], P &lt; 0.001), and farming (OR 2.71 [95% CI 1.71–4.29], P &lt; 0.001) were associated with an increased risk of EGPA. Co‐exposure to silica and farming yielded an OR of 9.12 (95% CI 3.06–27.19, P &lt; 0.001), suggesting a multiplicative effect between these 2 exposures. Smoking (current and former smokers combined) was significantly less frequent among patients with EGPA compared to controls (OR 0.49 [95% CI 0.29–0.70], P &lt; 0.001). The pack‐year index was also lower among patients with EGPA (OR 0.96 [95% CI 0.94–0.98], P &lt; 0.001). The association of silica and farming was primarily aligned with ANCA‐positive EGPA, while the association of smoking status and organic solvents was primarily aligned with ANCA‐negative EGPA. Conclusion The environment can influence susceptibility to EGPA. Exposure to silica, farming, or organic solvents is associated with an increased risk of EGPA, while smoking is associated with a lower risk. These exposures seem to have distinct effects on different EGPA subsets.
Abstract 12264: Mean Left Atrial Pressure Predicts Recurrence of Atrial Fibrillation After Endocardial Ablation: Results From a Single-Centre Prospective Cohort
Authors: Marc Badoz, Oussama Daou, Alexandre Guignier, Benoit Guillon, Salah Nouri, Florent Briand, Francois Schiele, Nicolas Meneveau
Journal: Circulation (2018)

Introduction: Catheter ablation is a mainstay of atrial fibrillation (AF) treatment. Certain risk factors for recurrence of AF have been identified, allowing tailored medical therapy and follow-up....
Correspondence on ‘Statistical review: frequently given comments’
Authors: Daisuke Waki, Masahiro Banno, Takashi Fujiwara
Journal: Annals of the Rheumatic Diseases (2021)

We read with great interest, the article by Lydersen, in which he summarised a number of issues indicated to authors as a statistical reviewer in the past.1

Although this article was published in 2015, it is still quite useful and instructive, especially in clinical research. However, we were concerned regarding the author’s advocacy of how to report summary statistics for continuous variables.

He suggests using the mean rather than median to describe the statistics for all types of data with …
Level 1 Evidence of Better Early Urinary Continence at 3 Months Following Robot-assisted Laparoscopic Radical Prostatectomy Compared with Laparoscopic Radical Prostatectomy. Results of the LAP-01 Randomised Controlled Trial
Authors: John W. Yaxley, Geoff Coughlin, Vipul Patel
Journal: European Urology (2021)
Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study
Authors: Gudula J A M Boon, Yvonne M Ende-Verhaar, Roisin Bavalia, Lahassan H El Bouazzaoui, Marion Delcroix, Olga Dzikowska-Diduch, Menno V Huisman, Katarzyna Kurnicka, Albert T A Mairuhu, Saskia Middeldorp, Piotr Pruszczyk, Dieuwertje Ruigrok, Peter Verhamme, Hubert W Vliegen, Anton Vonk Noordegraaf, Joris W J Vriend, Frederikus A Klok
Journal: Thorax (2021)

Background The current diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) is unacceptably long, causing loss of quality-adjusted life years and excess mortality. Validated screening strategies for early CTEPH diagnosis are lacking. Echocardiographic screening among all PE survivors is associated with overdiagnosis and cost-ineffectiveness. We aimed to validate a simple screening strategy for excluding CTEPH early after acute PE, limiting the number of performed echocardiograms. Methods In this prospective, international, multicentre management study, consecutive patients were managed according to a screening algorithm starting 3 months after acute PE to determine whether echocardiographic evaluation of pulmonary hypertension (PH) was indicated. If the ‘CTEPH prediction score’ indicated high pretest probability or matching symptoms were present, the ‘CTEPH rule-out criteria’ were applied, consisting of ECG reading and N-terminalpro-brain natriuretic peptide. Only if these results could not rule out possible PH, the patients were referred for echocardiography. Results 424 patients were included. Based on the algorithm, CTEPH was considered absent in 343 (81%) patients, leaving 81 patients (19%) referred for echocardiography. During 2-year follow-up, one patient in whom echocardiography was deemed unnecessary by the algorithm was diagnosed with CTEPH, reflecting an algorithm failure rate of 0.29% (95% CI 0% to 1.6%). Overall CTEPH incidence was 3.1% (13/424), of whom 10 patients were diagnosed within 4 months after the PE presentation. Conclusions The InShape II algorithm accurately excluded CTEPH, without the need for echocardiography in the overall majority of patients. CTEPH was identified early after acute PE, resulting in a substantially shorter diagnostic delay than in current practice.
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
Authors: JongBok Lee, Dilshad H. Khan, Rose Hurren, Mingjing Xu, Yoosu Na, Hyeonjeong Kang, Sara Mirali, Xiaoming Wang, Marcela Victoria Gronda, Yulia Jitkova, Neil MacLean, Andrea Arruda, Zoe Alaniz, Marina Y. Konopleva, Michael Andreeff, Mark D. Minden, Li Zhang, Aaron D Schimmer
Journal: Blood (2021)
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
Authors: D. Carbone, J. Lee, M. Kris, I. Wistuba, D. Kwiatkowski, D. Owen, P. Bunn, B. Johnson, F. Oezkan, Y. Tang, E.R. Parra, G. Lozanski, C. Rivard, K. Schulze, A. Nicholas, A. Johnson, J. Grindheim, D. Shames, S. Phan, E. Toloza, E. Haura, C. Mcnamee, J. Gainor, A. Patterson, S. Waqar, D. Raz, K. Reckamp, D. Finley, V. Rusch, J. Chaft, J. Abel
Journal: Journal of Thoracic Oncology (2021)
Breast cancer and COVID-19: Impact ofactive treatment on severe outcomes
Authors: K. Tawagi, J. Burton, M. Lunski, D. Maslov, J. Cole
Journal: Cancer Research (2021)

Background: Several reports have observed that cancer patients who recently underwent chemotherapy or surgeryhad a higher risk of severe events compared with patients without cancer  Limited data is available on outcomes inspecific cancer types, as well as the impact of non-cytotoxic systemic treatment, such as targeted therapy andhormonal therapy on severe outcomes  We aim to identify whether active treatment impacts severe outcomes (rateof hospitalization, ICU admission, intubation, and death) in breast cancer patients  Methods: We conducted amulticenter study in the state of Louisiana, throughout the Ochsner Health System, in both tertiary and non-tertiarycenters  Patients must carry a diagnosis of breast cancer, and have a completed SARS-CoV-2 test between March1st and April 30th, 2020  Chi-squared and Fisher's exact tests were performed to compare the proportion of patientsexperiencing severe outcomes between treatment groups  Results: As of April 30, 2020, a total of 70 patients withbreast cancer who had a positive SARS-COV-2 test were identified  Median age 64 5, median BMI 30 8, 62 9%(n=44) black, 27 1% (n=19) current/former smokers, HTN (n=52) and DM2 (n=22) were the most commoncomorbidities, and 12 9% (n=9) of patients had stage IV disease  Of these patients, 58 6% (n=41) were on hormonaltreatment, and another 12 9% (n=9) were receiving other forms of systemic therapy (cytotoxic chemotherapy ortargeted therapy)  In terms of severe outcomes, 32 9% (n=23) of patients required hospitalization, 8 6% (n=6)required ICU admission with 7 1% (n=5) patients requiring intubation, 11 4% (n=8) of patients died  There was not astatistical difference in rate of severe outcomes (rate of hospitalization, ICU admission, intubation, and death)among breast cancer patients receiving active treatment (chemotherapy, targeted therapy, or hormonal therapy) vs those receiving no active treatment  There was also no difference in terms of severe outcomes by race  Conclusion:With an ongoing global COVID-19 pandemic, it is important to identify how the treatment and management ofcancer impacts COVID-19 outcomes  This small cohort does not identify active treatment as a risk factor forincreased rate of severe outcomes in patients with breast cancer  Further analyses describing impact of specifichormonal and chemotherapy regimens on risk of hospitalization and death will be completed by time of presentation
P82.02 Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study
Authors: J. Beal, D. Gomes, P. Taranto, L. Koch, A.C. Rezende, M. Samano, B. Bibas, O. Gomes, P. Campregher, P. Severino, L. Marti, V. Paes, R. Chate, D. Sales, G. Schvartsman
Journal: Journal of Thoracic Oncology (2021)
Comment on Hásková et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. Diabetes Care 2020;43:2744–2750
Authors: Alexander Seibold
Journal: Diabetes Care (2021)

The Comparison of CGM in Randomized Study of Real-time and Intermittently Scanned Systems in T1D With Normal Awareness of Hypoglycemia (CORRIDA) study (1) has compared real-time continuous glucose monitoring (rtCGM) and intermittently scanned CGM (isCGM) (also termed flash glucose monitoring) in people with type 1 diabetes (T1D) during a 4-day exercise regimen and over 4 weeks at home. CORRIDA concluded that rtCGM is superior to isCGM in reducing the percentage of time below range (%TBR) and increasing the percentage of time in range (%TIR) in adults with T1D and normal hypoglycemia awareness. We must comment on the glucose sensor–derived conclusions reported.

First, all baseline data were collected using the iPro2 rtCGM device (Medtronic), whereas study outcomes used either the Guardian Connect Mobile rtCGM (Medtronic), which like the iPro2 …
The risk of community-acquired pneumonia in children using gastric acid suppressants
Authors: Linda J.T.M. van der Sande, Quirijn Jöbsis, Michiel A.G.E. Bannier, Ewoudt M.W. van de Garde, Jan J.M. Coremans, Frank de Vries, Edward Dompeling, Johanna H.M. Driessen
Journal: European Respiratory Journal (2021)

With the increased use of acid suppressants, significant potential complications such as community-acquired pneumonia (CAP) are becoming more apparent. Paradoxically, in spite of an increased focus on potential complications, there is an increased use of acid suppressants in children and a lack of data specifically targeting the association between acid suppressants and CAP. Our main objective was to evaluate the risk of CAP in children using acid suppressants (proton pump inhibitors (PPIs) and/or histamine-2 receptor antagonists (H2RAs)).We performed a cohort study using data from the UK Clinical Practice Research Datalink. All patients aged 1 month to 18 years with a prescription of acid suppressants were included and matched to up to four unexposed children. Time-varying Cox proportional hazards models were used to estimate the risk of CAP. The cohort consisted of 84 868 exposed and 325 329 unexposed children.Current use of PPIs and H2RAs was associated with an increased risk of CAP (adjusted hazard ratio 2.05 (95% CI 1.90-2.22) and 1.80 (95% CI 1.67-1.94), respectively). The risk was even greater in patients with respiratory disease. Long-term use (≥211 days) of PPIs and H2RAs led to a significantly greater risk of CAP compared with short-term use (<31 days). After cessation of therapy, the risk remained increased for the following 7 months.The use of acid suppressants in children was associated with a doubled risk of CAP. This risk increased with chronic use and respiratory disease, and remained increased after discontinuation of therapy.
Abstract P06: Anticancer agent 3-deazauridine has the potential to be effective against COVID-19 due to its inhibition of replication of RNA viruses
Authors: Richard Momparler
Journal: Clinical Cancer Research (2021)

Abstract 3-Deazauridine (3DU) is a nucleoside analogue that was investigated for its antineoplastic activity in cancer patients. 3DU after its phosphorylation in cells to its 5’-triphosphate is a potent inhibitor of CTP synthetase. Inhibition of this enzyme results in a reduction in cellular CTP and inhibition of RNA synthesis. This action of 3DU can also inhibit RNA synthesis since the viral RNA polymerase requires CTP for replication of RNA. 3DU was reported to inhibit the in vitro replication of the RNA influenza virus at concentrations in the range of 40 µM (1) and should also have the potential to inhibit the replication of SARS-CoV-2. In a pilot clinical study, we treated a patient with acute lymphoid leukemia with 3DU at doses ranging from 120 to 360 mg/kg using a continuous intravenous infusion ranging from 40 to 72 hr. (2). The objective of the study was to determine if 3DU could enhance the antileukemic action of the inhibitor of DNA methylation, decitabine, and overcome the problem of drug resistance to this deoxycytidine analogue. Partial responses were observed indicating that pharmacological action of 3DU could accomplish this objective. There were minimal signs of toxicity in this clinical study on 3DU which exhibited plasma concentrations of this analogue in the range that inhibit RNA virus replication. This observation suggests that it would be safe to use 3DU in patients with COVID-19. 3DU has a rapid onset of action with a significant sign of antineoplastic action observable after a 4 h in vitro treatment of human leukemic cells. This pharmacological property rapid action of 3DU may be very important in patients with advanced COVID-19 to inhibit the virus is during its rapid replication phase and prevent progression of the disease to acute lung inflammation. It would be interesting to test this hypothesis in advanced COVID-19 patients at high risk for disease progression. For an initial pilot study I recommend a 36 h infusion of 3DU at a total dose of 120 mg/kg. It is possible that therapy with 3DU may have the potential to rescue patients with advance COVID-19. References 1. Shannon, W.M., Arnett, G., Schabel, F.M., Jr., 1972. 3-Deazauridine: inhibition of ribonucleic acid virus-induced cytopathogenic effects in vitro. Antimicrob. Agents Chemother. 2, 159–163. 2. Raynal, N.J., Momparler, L.F., Rivard, G.E., Momparler, R.L., 2011. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk. Res. 35, 10-118. Citation Format: Richard Momparler. Anticancer agent 3-deazauridine has the potential to be effective against COVID-19 due to its inhibition of replication of RNA viruses [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr P06.
Abstract 15620: Diagnostic Performance of Ultra-high-resolution CT Coronary Angiography in Patients With Severe Coronary Artery Disease: Initial Experience
Authors: Jacqueline M Latina, Mahsima Shabani, Karan Kapoor, Jaclyn Sesso, Jeffrey Trost, Shadpour Demehri, Mahadevappa Mahesh, Joao Ac Lima, Armin Zadeh
Journal: Circulation (2020)

Introduction: Conventional resolution coronary CTA (CRCT) is frequently avoided in patients with heavy calcification and prior stents given the diminished diagnostic accuracy. Ultra-high-resolution CT (UHRCT) with detector width of 0.25 mm may overcome partial volume effect limitations. Hypothesis: We hypothesize that UHRCT yields high accuracy for detecting obstructive coronary arterial stenoses in patients with severe coronary artery disease using cardiac catheterization as reference standard. Methods: Nine patients ≥45 years with severe coronary artery disease referred for invasive coronary angiography were prospectively enrolled at a single center. Patients underwent UHRCT within 30 days prior to catheterization and results for significant coronary artery stenoses (≥70%) by visual assessment by blinded expert readers for the two tests were compared. Diagnostic accuracy assessment was performed at a patient-level (N=9) and vessel-level (N=36). Results: Median patient age was 67 (range 53-77). Six patients were obese and 6 had prior stent placement. Estimated radiation dose was 9.3 mSv. Mean Agatston calcium score of patients without stents was 1,688. UHRCT correctly classified all patients as having obstructive or non-obstructive coronary heart disease, respectively, yielding 100% accuracy (95% confidence interval [CI] 64-100%). On a vessel level UHRCT had an accuracy of 93% (95% CI 78-98%). Conclusions: Our initial experience with UHRCT in patients with severe coronary calcification or prior stenting suggests high accuracy for detecting and excluding obstructive stenoses. These results warrant further studies to confirm a role of UHRCT in this challenging population.
Abstract 14807: Limited Impact of ACC/AHA Guidelines on Dual Antiplatelet Use Following Coronary Artery Bypass Grafting in Acute Myocardial Infarction
Authors: Jared P Beller, William Z Chancellor, J H Mehaffey, Robert B Hawkins, Alan M Speir, Mohammed A Quader, Leora T Yarboro, Gorav Ailawadi, Nicholas R Teman
Journal: Circulation (2018)

Introduction: Current ACC/AHA guidelines recommend one year of dual antiplatelet therapy (DAPT) after CABG in the setting of acute myocardial infarction (AMI). We sought to evaluate the impact of t...
Intranasal Naloxone Administration
Authors: Rafael Ortega, Ala Nozari, William Baker, Sannoor Surani, Melinda Edwards
Journal: New England Journal of Medicine (2021)

Intranasal naloxone is used to treat patients with respiratory and central nervous system depression that is known or suspected to be caused by an opioid overdose. This video demonstrates the administration of intranasal naloxone.
HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens
Authors: Elizabeth Marrett, Winghan Jacqueline Kwong, Jipan Xie, Ameur Manceur, Selvam Sendhil, Eric Wu, Raluca Ionescu-Ittu
Journal: Journal of the National Comprehensive Cancer Network (2021)

"HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens" published on 17 Mar 2021 by National Comprehensive Cancer Network.
P23.01 “Multidisciplinary Approach for the Management of Primary Tracheal Carcinoma”- Institutional Experience of 9 Bangladeshi Cases.
Authors: M. Rahman, Q. Chowdhury, F. Begum, M. Nurunnabi, M. Islam, M. Hassan, M. Sarkar, M. Khair, S. Begum, M. Parvez, A.K.M. Haque
Journal: Journal of Thoracic Oncology (2021)
P50.11 Long-Term Survival after Surgical Resection of Carcinoid Tumors in a Population-Based Cohort
Authors: M. Taylor, M. Smeltzer, R. Ramirez, C. Fehnel, O. Akinbobola, L. Mchugh, A. Halal, P. Levy, D. Talton, H. Wiggins, E. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2021)
P40.01 Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
Authors: D. Bafunno, A. Catino, V. Lamorgese, D. Galetta, V. Longo, A. Mastrandrea, M. Montrone, F. Pesola, I. Marech, S. Cassiano, P. Petrillo, P. Pizzutilo, D. Ricci, N. Varesano, A. Zacheo
Journal: Journal of Thoracic Oncology (2021)